Publications in collaboration with researchers from Helsinki University Central Hospital (9)

2023

  1. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023

    European Journal of Cancer, Vol. 195

2021

  1. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

    European Journal of Cancer, Vol. 158, pp. 156-168

  2. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features

    Journal of the European Academy of Dermatology and Venereology, Vol. 35, Núm. 3, pp. 658-668

  3. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*

    British Journal of Dermatology, Vol. 184, Núm. 3, pp. 524-531

  4. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

    British Journal of Dermatology, Vol. 184, Núm. 4, pp. 722-730

2017

  1. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017

    European Journal of Cancer, Vol. 77, pp. 57-74

2011

  1. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

    Blood

2008

  1. Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification, and prognostic factors: An EORTC Cutaneous Lymphoma Group Study of 83 cases

    Blood, Vol. 111, Núm. 2, pp. 838-845

2006

  1. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

    European Journal of Cancer, Vol. 42, Núm. 8, pp. 1014-1030